Get the Stockscreener App
785.03
0.78%
-6.21
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $785.03, with a volume of 2.44M.
It is down -0.78% in the last 24 hours and up +3.65% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$791.24
Open:
$789.95
24h Volume:
2.44M
Relative Volume:
0.62
Market Cap:
$724.64B
Revenue:
$49.00B
Net Income/Loss:
$11.11B
P/E Ratio:
63.88
EPS:
12.29
Net Cash Flow:
$-1.27B
1W Performance:
-2.92%
1M Performance:
+3.65%
6M Performance:
+2.66%
1Y Performance:
-11.94%
1-Day Range:
$779.44
$790.62
1-Week Range:
$779.44
$825.00
52-Week Range:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
785.03 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
150.73 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
74.01 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.49 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.96 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug - Reuters
Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly - The Malaysian Reserve
Eli Lilly’s SWOT analysis: stock poised for growth amid challenges in GLP-1 market - Investing.com
Eli Lilly genetic medicine acquisition to address cardiovascular risk - European Pharmaceutical Review
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks
Eli Lilly (LLY): Bariatric Surgery Outperforms GLP-1 Drugs in We - GuruFocus
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga
More Than a One Trick Pony, Lilly Feeds Success Back Into Biotech - BioSpace
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. - The Globe and Mail
Eli Lilly Stock Dips (18 Jun): Analyzing the Drop and What Traders Should Do Next - Daily Chhattisgarh News
UBS reiterates buy rating on Eli Lilly stock following Verve acquisition - Investing.com
Eli Lilly stock price target maintained at $1,100 by Bernstein on Verve deal - Investing.com Canada
Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug - rrdailyherald.com
Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers
Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition - PMLiVE
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus
Eli Lilly acquisition of Verve signals renewed interest in gene editing - Investing.com
Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com
Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play - Insider Monkey
In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech
Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com
Eli Lilly to buy gene-editing biotech Verve for $1.3 billion - The Boston Globe
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs - upi.com
Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn - Pharmaceutical Technology
Eli Lilly (LLY) 5-Year Growth Surges Over 383%, Showcasing Enduring Strength Beyond Daily Market Moves - Daily Chhattisgarh News
Eli Lilly LLY (NYSE:LLY) Expands Biotech Reach With Verve Deal Talks Dow Jones Industrial Average - Kalkine Media
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - MSN
UBS Maintains Price Target on Eli Lilly (LLY) Despite CVS Shift to Wegovy - Insider Monkey
Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - TradingView
Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize
Lilly acquires cardiovascular genetic medicine company for up to $1.3B - Inside INdiana Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B - Cardiovascular Business
Lilly to acquire Verve in $1B bet on gene editing for heart disease - BioPharma Dive
Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion - Yahoo
Verve Therapeutics Soars 75% After Eli Lilly Buyout - Wall Street Pit
Eli Lilly Expands Gene-Editing Arsenal With Verve Acquisition - Finimize
Lilly adds highest Zepbound doses to DTC offering - STAT
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly - MSN
Eli Lilly to Buy Gene-Editing Biotech Verve for $1.3 Billion - Bloomberg
Liking what it sees, Lilly to buy base editing partner Verve for $1.3B - FirstWord Pharma
Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push - Reuters
Eli Lilly Stock Dives Today: A Trader’s Analysis of Key LLY Metrics - Daily Chhattisgarh News
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - Mint
Lilly to Acquire Verve Therapeutics for Up to $1.3B - Genetic Engineering and Biotechnology News
Eli Lilly acquires biotech company for USD 1.3bn - medwatch.com
Lilly to buy gene-editing partner Verve for up to US$1.3 billion in cardiac care push - CP24
Verve soars after Eli Lilly announces $1.3 billion acquisition of gene-editing company - Sherwood News
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade) (NYSE:LLY) - Seeking Alpha
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lilly Eli Co Stock (LLY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yuffa Ilya | EVP & President, LLY Int'l |
May 14 '25 |
Sale |
749.24 |
1,250 |
936,550 |
27,510 |
1.08%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):